Helsinki-based TILT Biotherapeutics raises $2M for ovarian cancer immunotherapy research
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, has been awarded a $2M grant from the U.S Department of Defense (DOD). Helsinki-based TILT Biotherapeutics is recognised as one of
Helsinki-based TILT Biotherapeutics raises $2M for ovarian cancer immunotherapy research Read More »









